A B S T R A C T α-Synuclein (αS) and tau have a lot in common. Dyshomeostasis and aggregation of both proteins are central in the pathogenesis of neurodegenerative diseases: Parkinson's disease, dementia with Lewy bodies, multi-system atrophy and other 'synucleinopathies' in the case of αS; Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy and other 'tauopathies' in the case of tau. The aggregated states of αS and tau are found to be (hyper)phosphorylated, but the relevance of the phosphorylation in health or disease is not well understood. Both tau and αS are typically characterized as 'intrinsically disordered' proteins, while both engage in transient interactions with cellular components, thereby undergoing structural changes and context-specific folding. αS transiently binds to (synaptic) vesicles forming a membrane-induced amphipathic helix; tau transiently interacts with microtubules forming an 'extended structure'. The regulation and exact nature of the interactions are not fully understood. Here we review recent and previous insights into the dynamic, transient nature of αS and tau with regard to the mode of interaction with their targets, the dwell-time while bound, and the cis and trans factors underlying the frequent switching between bound and unbound states. These aspects are intimately linked to hypotheses on how subtle changes in the transient behaviors may trigger the earliest steps in the pathogenesis of the respective brain diseases. Based on a deeper understanding of transient αS and tau conformations in the cellular context, new therapeutic strategies may emerge, and it may become clearer why existing approaches have failed or how they could be optimized.
Introduction
In a sense, the study of protein folding is a quandary: conventional NMR, cryo-EM, or X-ray crystallography can solve the structure of a purified protein but does so by taking the protein out of its biological context. On the other hand, various cell biological and biochemical techniques can provide insight into a protein's behavior within a cellular context, but the information on its structure at atomic-level resolution is limited. That does not seem to be a problem for many proteins because their in vitro structures are a good approximation of those in the cell. However, it becomes a greater challenge when studying 'intrinsically disordered' proteins. Such proteins (or at least significant portions of them) adopt a more-or-less random-coil ('unfolded') structure in solution in vitro, but this does not rule out that context-specific folding/assembly states can arise inside cells. On the contrary, for many 'intrinsically disordered' proteins, transient folding has been proposed, but the dynamic nature of such states can render the proteins elusive to precise characterization. The stakes arguably become higher when the proteins under investigation are implicated in disease. Indeed, two key proteins in neurodegenerative diseases, α-synuclein (αS) in Parkinson's disease (PD), Dementia with Lewy bodies (DLB), and other 'synucleinopathies' and tau in Alzheimer's disease (AD), frontotemporal dementia (FTD), and other 'tauopathies' are still not yet well understood regarding their dynamic conformational behavior in cells. αS and tau, which both form insoluble aggregates in the brain under disease conditions, have been described to be largely soluble in their native states while transiently interacting with cellular targets: αS with (synaptic) vesicles, tau with microtubules (MTs). This indicates that a contextual understanding of the transient and dynamic behavior of both proteins at the chemical, molecular, and cellular level may be required to understand synucleinopathies and tauopathies and develop therapeutic strategies through new perspectives. Here, we discuss recent advances in understanding cellular αS and tau dynamics in the context of the previous literature. Our special focus will be molecular 'cis' and 'trans' determinants undergirding αS and tau transient behavior. We conclude with some remarks on possible therapeutic strategies in light of our analysis.
αS

αS in health and disease
the precise structure and characteristics of physiological αS. There are many fine reviews on structure/function (Bendor et al., 2013; Mor et al., 2016; Villar-Piqué et al., 2016; Wang et al., 2016; Cremades et al., 2017) , genetic interactions (Schneider and Alcalay, 2017; Nussbaum, 2018) , and neurotoxicity Villar-Piqué et al., 2016; Berrocal et al., 2015; Ghosh et al., 2015; Wong and Krainc, 2017; Roberts and Brown, 2015) of αS, but what is significant to highlight here is that despite years of research, the precise function, subcellular distribution, and context-specific behavior of αS are still under investigation. It is likely that these properties are all intimately linked.
In mature neurons, including dopaminergic neurons (George et al., 1995; Iwai et al., 1995) , αS predominantly resides in presynaptic nerve terminals, which has prompted the hypothesis that αS may be involved in regulating dopamine release (Murphy et al., 2000; Gedalya et al., 2009; Nemani et al., 2010) . Considerable evidence suggests that αS helps regulate (synaptic) vesicle trafficking (Abeliovich et al., 2000; Chandra et al., 2004; Nemani et al., 2010; Scott and Roy, 2012; Wang et al., 2014; Vargas et al., 2014; Logan et al., 2017) . This role of αS is consistent with its well-documented propensity to bind to small vesicles in vitro, which is mediated by its formation of transient amphipathic helices at highly curved membranes (see 2.2) (Davidson et al., 1998; Chandra et al., 2003; Jao et al., 2004 Jao et al., , 2008 . PD and DLB cytopathology and neurodegeneration are characterized by αS accumulation into Lewy bodies, large intracellular aggregates whose major component is αS. However, the exact relationship between these lesions and dopaminergic neuronal death in the substantia nigra pars compacta and eventual PD symptoms, such as bradykinesia and muscular tremors (Kalia and Lang, 2015) , is not fully understood. Similarly, we lack understanding of the exact pathogenic significance of cortical Lewy bodies in DLB. How and under what conditions αS aggregates have been areas of much inquiry and debate.
αS transiently binds to synaptic vesicles
Early biochemical characterizations of purified bacterially-expressed αS identified the protein to be soluble (George et al., 1995; Irizarry et al., 1996) , which confirmed previous immunogold-EM data that detected αS throughout the cytoplasmic matrices in axon terminals (Nakajo et al., 1994) . Subsequent biophysical and biochemical studies, however, reported that αS can bind to small unilamellar and multilamellar vesicles (Davidson et al., 1998; Jo et al., 2000) and detergent micelles (Eliezer et al., 2001) . Chemically crosslinked αS in SH-SY5Y cell homogenates was also identified in vesicle fractions by flotation centrifugation (Kim et al., 2006) , but this observation did not seem to directly contradict the generally soluble nature of αS, because fractionated brain extracts revealed only a weak association of αS with synaptic vesicles (Kahle et al., 2001; Fortin et al., 2004) . Similarly, photobleaching microscopy indicated that αS interacts only weakly with membranous elements of the nerve terminal, and each molecule appears to switch rapidly between the aqueous cytosol and the membrane (Fortin et al., 2004 (Fortin et al., , 2005 . While methods to interrogate the function of αS vis-à-vis synaptic vesicles (Bendor et al., 2013; Burré, 2015; Lou et al., 2017; Logan et al., 2017; Almandoz-Gil et al., 2018; Liang and Tamm, 2018; Zhang et al., 2018) became a natural implication of such studies, this function is still not well understood (for other proposed functions, see review by Bendor et al., 2013) . Nevertheless, what has emerged is a nuanced picture of αS -an aqueously soluble protein that can transiently interact with vesicular membranes.
Recent studies have supplemented established biophysical and microscopy techniques by using new technologies to quantify the transient nature of αS. Single-molecule microscopy combined with photobleaching identified an average of seventy αS molecules bound to each vesicle, with the αS molecules situated 10 nm apart from each other (Fakhree et al., 2016) . Moreover, the use of phospholipid bilayer nanodiscs, which had been previously used to study αS-Ca 2+ interactions (Zhang et al., 2014) , and bacterially purified αS allowed for αS-membrane association and dissociation kinetics to be calculated in vitro (e.g., an off-rate of 0.015 ± 0.006 s -1 ) (Viennet et al., 2018) . However, data generated by in vivo multiphoton fluorescence recovery after bleaching (FRAP) coupled with murine cranial window surgery were consistent with the existence of at least two pools of αS in terminals with lower levels of mobility than measured previously. The observed t 1/2 for axonal terminal photobleaching recovery (∼2 min) in the mice was much slower than that measured in a photobleaching study of GFP-tagged αS at presynaptic terminals in an acute dissociated hippocampal cell culture system (< 10 s) (Fortin et al., 2005) , or YFP-tagged αS in C. elegans body wall muscle (< 10 s) (van Ham et al., 2008) . In addition to the presynaptic terminal, the turnover and mobility of αS in the somatic compartment of cortical neurons was measured by Unni et al., 2010 . In contrast to the discrepancy between their presynaptic terminal results and those reported in the literature, the rapid mobility of αS-GFP measured within the soma (< 5 s) was in good agreement with these previous studies of αS mobility. This suggested that the cellular context of αS may influence transient binding affinity and kinetics (Unni et al., 2010; Spinelli et al., 2014) .
This state of equilibrium between soluble and membrane-associated forms of αS is expected to be finely balanced and tightly regulated. Familial PD mutations as well as engineered variants have been observed to shift the balance towards misfolding, insolubility, inclusion formation, and cell toxicity (Brucale et al., 2009; Lázaro et al., 2014; Dettmer et al., 2017; Íñigo-Marco et al., 2017) (discussed in further detail below). Consequently, such adverse changes in neuronal cells pose functional problems in vesicle trafficking, recycling, and neurotransmitter release (Xu et al., 2002 (Xu et al., , 2016 Lotharius et al., 2002; Busch et al., 2014) . Even overexpressed wildtype αS has been shown to undergo accelerated aggregation Raiss et al., 2016) and display many of the aforementioned phenotypes (Larsen et al., 2006; Nemani et al., 2010; Soper et al., 2008; Lundblad et al., 2012; Lautenschläger et al., 2018) . In short, these observations highlight the transient nature of wildtype αS and the importance for the molecule to remain dynamic to keep cell toxicity at bay.
αS transiently exists in a variety of monomeric and multimeric forms
Soluble αS had long been believed to exist solely as an unfolded monomer, both in vitro and in vivo. Less than a decade ago, emerging studies on the conformation of αS began to posit that the protein can exist in part physiologically as a soluble, higher-ordered multimer, principally a tetramer (Wang et al., 2011; Bartels et al., 2011; Dettmer et al., 2013; Gurry et al., 2013; Killinger and Moszczynska, 2016; Luth et al., 2015) . Several biochemical as well as in-cell NMR studies responded by defending the classical view of αS as a natively unfolded monomer in cells (Binolfi et al., 2012; Fauvet et al., 2012; Burré et al., 2013; Theillet et al., 2016) . A review on αS homeostasis (Dettmer et al., 2016) highlighted the debate and suggested specific reasons for why certain studies reported the successful purification of tetrameric/multimeric αS whereas others did not: 1) multimer stability might be tissuespecific (Bartels et al., 2011; Burré et al., 2013; Westphal and Chandra, 2013; Luth et al., 2015) ; 2) αS purification in vitro under non-denaturing conditions could stabilize multimers, but the exact parameters for successful multimer purification are not fully understood (Bartels et al., 2011; Gould et al., 2014; Mor et al., 2016) ; and 3) under certain conditions, an undiscovered multimer-stabilizing molecule (perhaps one or more lipid molecules) may be lost during purification (Luth et al., 2015) . Because of the difficulty of αS multimer purification and stabilization, intact-cell methods such as the application of cell-penetrant cross-linkers to cells and brain tissue (Dettmer et al., 2013 (Dettmer et al., , 2015a Dettmer et al., 2017; Kim et al., 2016; Nuber et al., 2018) . Yeboah, et al. Neurobiology of Disease 132 (2019) 104543 multimeric αS arrangements. Intact-cell NMR, an elegant method that was used to demonstrate the in vivo relevance of unfolded soluble αS (Theillet et al., 2016) , is 'blind' to multimeric or membrane-associated αS molecules (Alderson and Bax, 2016) . A crosslinking study that compared the outcome of crosslinking intact cells vs. lysates demonstrated that αS and βS putative tetramers (60 kDa) were prominent in intact cells but largely disassembled in crude cell lysates; only in highly concentrated ('crowded') cell lysates could some multimeric αS be trapped by crosslinking (Dettmer et al., 2013) . These findings were consistent with a model in which αS multimerization is highly dependent on the intact cellular environment. Relevant factors that promote αS multimerization inside cells could be general 'molecular crowding' or the transient but frequent interaction with specific cellular factors such as membrane lipids, organelles or other biomolecules. Obviously, dilution by cell lysis reduces crowding and disrupts any weak transient interactions that may exist. Recently, an elegant in vitro study demonstrated that transient αS-membrane interactions may indeed be the first step towards native αS-αS assembly (Rovere et al., 2018) . The authors investigated the interplay of αS with 13:0 phosphatidyl-choline small unilamellar vesicles. By modulating αS binding through phase transitions of the vesicle lipids, soluble helical αS species could be reconstituted that behaved as multimers. While folding of certain 'intrinsically disordered proteins' upon binding to ligands is well established, no previous report had described folding assisted by intermittent contact with a cofactor (in this case: membrane lipids). This remarkable study is in agreement with several reports on soluble αS multimers (Bartels et al., 2011; Dettmer et al., 2013 Dettmer et al., ,2015a Dettmer et al., 2017; Gould et al., 2014; Gurry et al., 2013; Iljina et al., 2016; Killinger and Moszczynska, 2016; Kim et al., 2018; Luth et al., 2015; Nuber et al., 2018; Trexler and Rhoades, 2012; Wang et al., 2011; Westphal and Chandra, 2013) . The relevance of multimeric αS at membranes has also been highlighted in other studies, e.g., in the context of mediating SNARE complex assembly Burré et al., 2015) and vesicle clustering (Wang et al., 2014) . Fig. 1A illustrates a model of dynamic cellular αS behavior in health, centered around the idea of (vesicle) membrane-assisted, transient αS folding and assembly (Rovere et al., 2018) . In this model, αS monomer and multimer levels are highly transient, dynamic, and sensitive to environmental factors. membranous non-fibrillar αS aggregation as an emerging concept Dettmer et al., 2017; Shahmoradian et al., 2019) (bottom left).
Molecular determinants of the transient nature of αS
Across the 140 amino acids that span αS, the protein is often subdivided into three regions: the N-terminal region (amino acids 1-60), the 'NAC' (non-amyloid component) domain (amino acids 61-95), and the C-terminal region (amino acids 96-140) (Mor et al., 2016) . The Nterminal region has been of immense interest to better understand the molecular determinants for αS transient membrane-binding behavior, because early studies identified this region to contain amino acid repeat motifs that resemble lipid-binding domains often observed in apolipoproteins (George et al., 1995) . Biochemical, cell biological and biophysical studies have shed much light on how αS 'cis' determinants (Fusco et al., 2014; Lokappa et al., 2014; Lee et al., 2016; Dettmer et al., 2017) and 'trans' factors such as vesicle membrane composition (Pfefferkorn et al., 2012; Zhang et al., 2014; Galvagnion, 2017; Rovere et al., 2018; Fecchio et al., 2018) may govern αS transient binding to artificial and biological membranes. Different regions of the protein have been shown to have different binding affinities for charged lipid membranes. The first 25 residues in the N-terminus have been suggested to 'anchor' into the bilayer , with certain key residues (M1, V3, F4, and L8) stabilizing αS at membranes via Van der Waals interactions, while other residues (K6, K10, and K12) interact electrostatically with negatively-charged lipid head groups (Pirc and Ulrih, 2015; Fusco et al., 2016) . Due to the repeated structure of αS (6-7 imperfect repeats of 11 aa with the consensus sequence of the repeat motifs being KTKEGV), this mechanism can be extended to the first~95 aa of the protein. The positively-charged Lys residues have been suggested to interact with negatively-charged lipid head groups when the N-terminus of αS forms a membrane-induced, amphipathic 11/3 helix (3.67 amino acids per turn) (Alderson and Markley, 2013) , which allows the Lys residues to lie perpendicular to the helical axis on a membrane (Jao et al., 2008) . In contrast, nonpolar amino acid residues can partially dip into the membrane bilayer (~1-5 Å below lipid head groups) (Wietek et al., 2013; Tsigelny et al., 2012; West et al., 2016; Cheng et al., 2013) , especially where lipid packing defects exist, and interact with the lipid carbon chains (Nuscher et al., 2004; Ouberai et al., 2013) . However, in the αS membrane-induced, amphipathic 11/3 helix, some non-polar residues are exposed to the aqueous phase, and some polar residues are embedded into the nonpolar lipid bilayer, most prominently threonine residues (see Fig. 2 ), leading to imperfect amphipathic helix formation.
Consequently, the specific arrangement of charged residues, polar lipid head groups, and nonpolar carbon chains seems to manifest the transient nature of αS-membrane binding (Wang et al., 2016; Dettmer et al., 2017) .
This principle can be confirmed by observing how rationally engineered mutants within the canonical repeat motif, KTKEGV, that 'correct' the imperfect hydrophobicity within the hydrophobic half of the αS membrane-induced amphipathic helix can thereby abolish the transient nature of αS (Dettmer et al., 2015b Pranke et al., 2011; Harada et al., 2009) . Six or seven repeats of a KLKEGV or KTKEIV or KTKKGV mutant can destabilize native tetramers/multimers in neurons and presumably lead to the accumulation of helical monomeric αS at membranes and perhaps some unfolded cytosolic αS. These mutants remained monomeric when tested by DSG crosslinking and were highly enriched in PBS-insoluble fractions that required Triton-X 100 to solubilize membranes (Dettmer et al., 2015b) . Beyond such artificially engineered αS, an amplification of the E46K fPD-linked mutant (i.e., KTKKGV in repeat 4) in the two adjacent repeat motifs strongly reduces tetramers/multimer levels, as suggested by intact cell-crosslinking and YFP-fluorescent-protein complementation assays. αS '3K' also accumulates in PBS-insobluble fractions (Dettmer et al., 2015a . In addition, the mutant H50Q was reported to decrease αS solubility 10-fold (Porcari et al., 2015) . However, also the membrane-binding deficient, cytosol-enriched fPD variants A30P and G51D cause PD, and it was suggested that they expose their hydrophobic core in solution, thus enabling other αS molecules to bind and aggregate (Ysselstein et al., 2015) . A study based on intact-cell crosslinking and YFP complementation concluded that all known fPD-linked αS variants lead to a relative decrease of αS multimers and a gain in aggregation-prone monomers, either in the cytosol or at membranes, depending on the specific mutants (Dettmer, 2018; Dettmer et al., 2015a) . In short, Top left: the 140-aa sequence of human wildtype αS contains 9 semi-conserved 11-aa repeats with the core consensus motif 'KTKEGV'. Highly conserved repeats are indicated in dark grey, poorly conserved repeats in light grey. Bottom left: color-coded schematic of repeats 1-7 of human αS by aligning the aa sequence via the KTKEGV motifs. Blue indicates basic (light blue: histidine), red: acidic, purple: polar uncharged, and black: non-polar residues. In addition to KTKEGV, the polar character of positions 1 and 9 as well as the non-polar, hydrophobic character of positions 8, 10, and 11 are relatively well conserved. Repeats 1-9 are interrupted only once: by 'ATVA' between repeat 4 and 5. Right: Color-coded schematic of αS repeats 1-7 (omitting 'ATVA' between repeats 4 and 5) in an 11/3 helical wheel, embedded in the outer leaflet of a curved vesicle membrane (negatively charged lipid head-groups in red, fatty acid 'tails' in black). The helix is stabilized by hydrophobic interactions (grey area) and electrostatic interactions (blue area). Certain structural aspects such as the presence of polar threonines as well as the small and 'helix-breaking' glycine prevent the formation of a highly stable helix.(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) F. Yeboah, et al. Neurobiology of Disease 132 (2019) 104543 certain regions of αS as well as specific residues have been shown to play a role in either increasing or decreasing binding affinities to lipid bilayers through electrostatic or Van der Waals interactions; increasing αS dwell-time either in the cytosol or at membranes both seem to decrease multimerization, with negative consequences on cell health, as evidenced by the αS fPD-causing variants. Lastly, post-translational modifications add nuance to αS proteostasis. αS phosphorylation is of particular interest because 90% of aggregated αS present in Lewy bodies were reported to be phosphorylated at serine 129 (pS129) (Fujiwara et al., 2002) , implying that this specific phosphorylation event is connected to pathology (Fig. 1B) . In addition to the largely insoluble Lewy bodies, however, soluble pS129 αS has been found in CSF samples from PD patients and even controls e.g., Wang et al. (2012) . Growing evidence also indicates that Lewy bodies can contain large amounts of pS129-positive αS without being fibrillary, e.g., a very recent study by Shahmoradian et al. (2019) . The interplay between pS129 and αS tetramerization/multimerization has not yet been studied. Moreover, it has been proposed that pS129 may actually be a neuroprotective mechanism to accelerate the clearance of aggregated αS (Machiya et al., 2010; Oueslati, 2016) . This may be achieved at least with the aid of PLK-2 . Still other groups have concluded that rather than neurotoxic or neuroprotective roles for pS129, it serves a normal regulatory function in αS turnover (Tenreiro et al., 2014) and even in controlling gene expression (Pinho et al., 2019) . In short, whether pS129 unequivocally indicates pathology under all circumstances is unclear. The trigger for pS129, whether certain kinases phosphorylate only when αS interacts with membranes, or whether a 'master kinase' exists may all be important questions, the answers to which might further reveal whether pS129 plays multiple roles in contributing to synucleinopathy.
Tau
Tau in health and disease
One of the hallmarks of AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), Pick's disease, and other neurodegenerative diseases collectively called tauopathies are the so-called neurofibrillary tangles (NFTs), which consist mainly of aggregated tau protein (Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Wood et al., 1986; Wolozin et al., 1986) . There are numerous efforts to target tau with the hope of slowing disease progression and subsequent cognitive decline. In the case of AD, this is done in addition to targeting amyloid beta, the other, more upstream neuropathological hallmark of AD (Hardy and Selkoe, 2002) . Interestingly, the level of dementia in AD patients and AD animal models may correlate well with tau lesions (Braak and Braak, 1996; Nelson et al., 2012; Golde, 2014 ) -one of several reasons to thoroughly examine the therapeutic potential of tau. Since the discovery of tau from porcine brain MT fractions in 1975 (Weingarten et al., 1975) and its identification as the main NFT component (Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Wood et al., 1986; Wolozin et al., 1986) , major advances have been made in understanding the biology of tau, especially focusing on its aggregation and hyper-phosphorylation in tauopathies (Weingarten et al., 1975; Lee et al., 2001) .
Tau is an MT-associated protein (MAP) that may be involved in regulating MT stability (see 3.2-3.4.). The tau protein exists in six isoforms ranging in size from 352 to 441 amino acids as a result of alternative splicing of exons (Goedert et al., 1989) . The isoforms are marked by the presence or absence of exons 2, 3, and 10 and are regulated based on the stage of development of the brain, though their specific function is not known . The isoforms are named based on how many MT binding repeats (R) are expressed, with the 3R isoform having three MT binding repeats and the 4R isoform four binding repeats (Lee et al., 2001) . The 3R isoform is expressed mainly during the early development stage of the brain and the 4R isoform is expressed later in adulthood (Goedert et al., 1989; Kosik et al., 1989) . Most of what we know about tau originates from its function in neuronal cells. Besides its neuronal expression, tau was found to be expressed in non-neuronal tissues such as liver, muscle, kidney, and even cancer cell lines (Rouzier et al., 2005; Kenner et al., 1994) . Tau's characterization as an 'intrinsically disordered' protein in solution, while having numerous (proposed) functions within the cell, challenged the thought that proteins have to be pre-folded to exhibit specific functions in a cell (Goedert et al., 1991; Lee and Trojanowski, 1992) .
Tau transiently binds to MTs
As one of the three major component of the cytoskeleton, MTs control the formation of mitotic spindles, cilia, and flagella, and play an important role in cell motility and polarity (Viswanadha et al., 2017; Barlan and Gelfand, 2017) . MTs are built from α-and β-tubulin monomers into long, cylindrical, hollow-shaped protofilaments. MTs undergo dynamic changes between growth and shortening known as dynamic instability (Mitchison and Kirschner, 1984) . Individual MT polymers elongate by the addition of GTP-tubulin dimers to the end of the MT and shrink due to the competitive activity of end-binding proteins, preventing new tubulin dimers to bind (Akhmanova and Steinmetz, 2008; Akhmanova and Steinmetz, 2015) . A group of proteins known as MAPs binds to and promotes the assembly and stabilization of MTs. Tau is a MAP that transiently interacts with MTs to regulate their dynamics and spatial organization. In addition, tau is believed to stabilize MTs in axons which serve as 'roads' for transport within the cell (Hirokawa and Takemura, 2005) . There are many proposed mechanisms for the MT-associated function of tau (Choi et al., 2009; Butner and Kirschner, 1991; Santarella et al., 2004) . Several lines of investigation substantiate that tau bridges linear rows of tubulin dimers, by binding to several protofilaments via its MT-binding repeats (Al-Bassam et al., 2002; Kar et al., 2003) . Others have shown that tau stabilizes MTs by bridging the interfaces of tubulin heterodimers (Kadavath et al., 2015a) . Recent findings, however, suggest that tau may not stabilize axonal MTs at all, but rather modifies the biology of MTs by enabling them to have long labile domains (Qiang et al., 2018; Baas and Qiang, 2019) . Various techniques such as protein biochemistry and NMR have been used to delineate the physical and structural basis of the transient tau-MT interaction leading to different hypotheses/models about the interplay between these two binding partners.
It has been suggested that a dynamic equilibrium between free tau and tau bound to MTs is dictated by tau phosphorylation and dephosphorylation cycles (Ballatore et al., 2007; Biernat et al., 1993; Scott et al., 1993) . Phosphorylation sites such as Ser262, Ser365, Ser205, and Thr231 are typically considered to reduce the strength of the interaction between tau and MTs when phosphorylated (Ballatore et al., 2007) . Tau phosphorylation was proposed to alter its conformation and affinity to MTs, leading to a detachment from MTs (Jho et al., 2010; Fischer et al., 2009 ). In line with this idea, dysregulation of certain kinases has been proposed to perturb or even eliminate tau's MT binding in models of tauopathies (Trinczek et al., 1995; Sun and Gamblin, 2009; Leger et al., 1997) . While tau hyper-phosphorylation is certainly a hallmark of tauopathies, recent studies challenge the view that phosphorylation cycles are the key mechanism underlying transient (instead of stable) tau-MT interaction. In various binding and decay assays, it was shown that tau may be bound on each MT filament for only ∼40 ms (Janning et al., 2014) . This dwell-time is~100 times shorter than previously reported (Konzack et al., 2007) and too short for regulation by kinases: the average catalytic ability of a kinase is approximately 10 interactions per second (Newton, 1995) . Hence, a 'kiss-and-hop mechanism' of regulating tau-MT interaction was proposed (Janning et al., 2014) . Rather than a phosphorylation/de-phosphorylation mechanism of controling the transient MT-tau interaction, the authors suggest that tau may 'hop' between MTs in an undirected manner. Despite its high F. Yeboah, et al. Neurobiology of Disease 132 (2019) 104543 mobility, it was postulated that tau can shift the tubulin equilibrium toward polymerization: the short interaction time between tau and MTs was proposed to suppress the natural dissociation of tubulin dimers. Janning et al. further speculate that the rapid kiss-and-hop interaction that they observe may explain why tau, although binding to MTs, does not interfere with axonal transport. It is worth noting that the 'kiss and hop' model was developed in PC12 cells which do not express axonal components. Therefore, the distance between two MTs is~70 nm instead of the average~20 nm for MT-MT interactions (Jacobs and Stevens, 1986) . It is conceivable that details of the protein conformation and the effect of phosphorylation amongst others are model-dependent (Narayanan et al., 2010) . While probably not regulating the binding/unbinding cycles per se, its exact phosphorylation state is still expected to contribute to tau's overall MT binding affinity (see Fig. 3B ).
Reduced MT binding may in turn cause accumulation in the cytsosol and aggregation. Fig. 3A summarizes several aspects discussed in this paragraph and emphasizes the proposed kiss-and-hop mechanism of the tau-MT interaction (Janning et al., 2014) . Fig. 3B illustrates potential patho-mechanisms of AD, FTD, and other tauopathies in the context of impaired tau-MT interaction.
Lack of strong evidence for physiological multimeric forms of tau
The tau literature does not provide ample evidence for the existence of native tau higher-order assemblies. One study (Rosenberg et al., 2008) employed a surface force apparatus to determine the force profile for each of six tau isoforms physisorbed through self-assembly from solution to negatively charged mica surfaces. The authors interpreted their data as incompatible with tau acting on MTs as a monomer and speculated that two tau molecules may associate in an antiparallel configuration. This structure was suggested to be held together by an electrostatic 'zipper' of complementary salt bridges composed of the Nterminal and central regions of each tau monomer, with the C-terminal MT-binding regions extending outward from each end of the dimeric backbone. This tau dimer would then determine the length and strength of the linker holding two MTs together and to be the fundamental structural unit of tau, underlying both its normal and pathological action. Independent confirmation of such a mechanism is lacking.
Molecular determinants of the transient nature of tau
Tau is typically characterized as consisting of an N-terminal-, a proline-rich, an MT-binding domain (MBD), and a C-terminal domain (Fig. 4) . As is evident from their name, the MT-binding domains are important for MT interactions (Goedert et al., 1989; Mandelkow et al., 1996) . Each isoform of tau has three to four repeats ('R-repeats') located in the C-terminus (Goedert and Jakes, 1990) . Using synthetic tau fragments, it has been shown that these repeats form MT-binding units F. Yeboah, et al. Neurobiology of Disease 132 (2019) 104543 (Himmler et al., 1989; Lee et al., 1989) . Positively charged repeat sequences of the MBD were proposed to interact with negatively charged residues in tubulin and hence to facilitate the tau-tubulin interaction (Kar et al., 2003; Jho et al., 2010) . Recent studies based on NMR (Kadavath et al., 2015b) and cryo-EM (Kellogg et al., 2018) provide detailed insight into a complex mode of interaction. Both studies reiterate the previous notion that MT-bound tau does not become helicalin contrast to vesicle-bound αS that forms membrane-induced amphipathic 11/3 helices. Instead, tau adopts an 'extended' secondary structure, a state that is both different from unfolded and from helically or beta-sheet folded. In the extended structure, each of tau's R-repeats was observed to span both intra-and inter-dimer interfaces, centered on αtubulin and connecting three tubulin monomers (Fig. 4) . In each individual interaction site, key tau residues engage in specific interactions with key MT residues. Examples from the cryo-EM study (Kellogg et al., 2018) are: Ser258 and Ser262 in tau form hydrogen bonds with α-tubulin Glu434. Tau's conserved Lys259 interacts with an acidic α-tubulin patch formed by Asp424, Glu420, and Glu423. Ile260 is buried within a hydrophobic pocket formed by α-tubulin's Ile265, Val435, and Tyr262 at the inter-dimer interface. Lys267 may be positioned to interact with the acidic α-tubulin C-terminal tail. The universally conserved Ser262 was proposed to be critically involved in tight contacts with tubulin near a polymerization interface. The new structure thus now offers a detailed explanation for how Ser262 phosphorylation may disrupt tautubulin interactions. What these new studies leave open, however, is why tau binding to MTs is actually dynamic, and tau's dwell-time on MTs is so short. Importantly, the studies should not be misinterpreted as evidence for the presence of stable MT-tau assemblies within cells. The authors do not point to specific amino acids that are 'sub-optimal' for achieving energetic minima (such as the central threonine in the hydrophobic half of αS membrane-associated helices; see Fig. 2 ). The rapid switch of tau between soluble and MT-bound tau suggests that the energetic minimum of the soluble unfolded state is similar to that of the MTbound state(s). Though it may contribute to it, Ser262 phosphorylation is not expected to be the sole reason for tau's dynamic behavior, for reasons discussed in Section 3.2.
While the 2015 and 2018 structural studies mainly focused on the R-repeats, the proline-rich regions in tau are also believed to influence the tau-MT interaction (Lewis et al., 1989; Kanai et al., 1992) . The proline regions line the repeat domain of tau and may initiate the formation of the tau-MT interaction by binding to the MT-binding repeats of tubulin, a 'green light' to trigger tau-MT interactions (Butner and Kirschner, 1991; Gustke et al., 1994) . Notably, there are many phosphorylation sites on the proline-rich region which may affect interactions with other proteins as well as tau-MT interactions (Steinhilb et al., 2007; Gong et al., 2005) . Mutagenesis studies on human tau isoforms revealed that loss of the proline-rich domains reduces MT binding (Kanai et al., 1992) . Tau mutants with a deletion of the repeat domain, but with an intact proline-rich domain, were found to still bind to MTs (Gustke et al., 1994; Preuss et al., 1997) . Combining the prolinerich regions with the adjacent repeat regions increased the binding affinity of tau 10-fold compared to mutants lacking the proline-rich region (Goode et al., 1997) . Taken together, the data show that the proline-rich domain and the repeat regions in tau synergistically promote its MT binding. Accordingly, Mandelkow and colleagues proposed the 'jaws' model of MT-tau interaction to explain these observations (Preuss et al., 1997; Mukrasch et al., 2007) . Mutants of tau with deletions or multiplications of different domains were generated and tested for tau-MT interactions in cells. The authors found evidence for the binding of tau with MTs in the absence of the repeat regions. However, these mutants were unable to stabilize MTs. Increasing the number of repeats in the repeat region enhanced the interaction and effect of tau on MTs. On the other hand, mutants with deletion of the proline-rich regions flanking the repeat regions showed only low affinity to MTs and did not induce reorganization of the MTs. The authors concluded that the proline-rich regions flanking the binding repeats serve as targeting domains to position tau on the MTs and that the repeat domain act as the primary interacting domains, hence the 'jaw' model of tau-MT interaction (Preuss et al., 1997) . According to the authors, stabilization of MTs is only achieved if both domains of tau act together.
Therapeutic intervention via correcting transient behaviors of αS and tau?
The transient behavior and context-specific folding of αS and tau is The proposed structure is neither unfolded nor helically or β-sheet folded. Instead, it is characterized as 'extended'. The exact molecular basis for a highly transient, instead of a strong binding to MTs will require further research.(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
F. Yeboah, et al. Neurobiology of Disease 132 (2019) 104543 not a contradiction to their frequent characterization as 'intrinsically disordered proteins' because this term can simply be interpreted as lack of a sole and fixed three-dimensional structure. However, all current major protein classes considered 'druggable' are stably folded in their native states. Proteins like αS and tau on the contrary seem to exist as heterogeneous conformational ensembles, which renders them unsuitable for standard rational drug design approaches (Joshi and Vendruscolo, 2015) . Nonetheless, several different small molecule strategies are currently under investigation, including: (1) stabilizing the proteins in their natively disordered states, (2) inhibiting interactions with binding partners, and (3) inducing allosteric inhibition (Joshi and Vendruscolo, 2015) . In agreement with scenario (1), Collier et al. (2017) proposed that the tricyclic antidepressant compound nortriptyline can inhibit the aggregation of αS by directly binding to the soluble, monomeric form. The authors further suggested that nortriptyline-mediated 'reconfiguration of the monomer' can inhibit the formation of toxic conformations of the protein. Similarly, a recent study reported that stabilizing αS monomers with the polyphenol Oleuropein aglycone (OleA) reduced the likelihood for αS to aggregate into toxic molecules ) (see Singh et al., 2017 review for further comment on phenol-based strategies). More in line with scenario (2), Perni et al., 2017 demonstrated that squalamine (a natural product with proposed anticancer and antiviral activity that can be extracted from shark liver) can prevent αS aggregation by displacing αS from the surfaces of vesicles. This was suggested to block a first, membrane-assisted, step in the αS aggregation process. The same group then reported that the related compound trodusquemine not only inhibits αS-membrane interactions, but also blocks the fibril-dependent secondary pathways in the aggregation reaction, thereby effectively suppressing the toxicity of αS oligomers in neuronal cells (Perni et al., 2018) . However, other groups had suggested that pharmacological stabilization of monomeric αS in its helical form at membranes may inhibit pathogenic misfolding and aggregation (Fonseca-Ornelas et al., 2014) . Both approaches could in theory also turn out to be problematic since αS monomers both in membrane-associated (Galvagnion et al., 2015) and soluble conformations (Conway et al., 1998 (Conway et al., , 2000 Burré et al., 2015) have been reported to be aggregation-prone. Thus, another attractive option of preventing αS aggregation would be stabilizing native multimeric/tetrameric states of αS that have been reported to be aggregation-resistant (Iljina et al., 2016; Bartels et al., 2011) . An example of the direct stabilization of a tetrameric protein via a small molecule, thereby preventing amyloidosis, is the drug tafamidis, which stabilizes transthyretin (Johnson et al., 2012) . While the design of direct stabilizers of αS tetramers may depend on the successful generation of αS tetramer/multimer high-resolution structural data, it was recently shown that stabilizing native αS assembly can be achieved in an indirect fashion: the inhibition of stearoyl-CoA-desaturase (SCD) can increase αS multimer:monomer ratios in the multimerization-deficient familial-PD-linked mutant E46K (Fanning et al., 2018) . The exact mechanism is not clear, but it seems likely that blocking the SCD-catalyzed production of oleic acid (18:1) causes a reduced occurrence of this fatty acid in membrane lipids, leading to higher levels of saturated fatty acids. A higher degree of saturation has been reported to interfere with αS-membrane interaction because 'membrane defects' that favor αS binding are less likely to occur (Nuscher et al., 2004) . Thus, the correction of excess αS E46K membrane binding and the correction of E46K's lack of multimerization seem to go hand in hand. The target SCD was confirmed in a different study that was based on αS (yeast) toxicity (Vincent et al., 2018) .
In the case of tau, a recent study investigated the structural basis of small molecule druggability of native tau monomers (Kiss et al., 2018) . As an example, the authors showed that methylene blue binds to monomeric full-length tau selectively with high affinity (K d = 86.6 nM). The authors interpret their study as evidence that tau can be a viable drug target for small molecules that bind to monomeric tau and influence the way in which the protein interacts among itself and with other proteins (Kiss et al., 2018) . Clinical trials based on methylene blue have thus far turned out to be rather disappointing (Wischik et al., 2015; Gauthier et al., 2016; Wilcock et al., 2018) . Authors' claims of some efficacy after a post-hoc subgroup secondary analysis have been controversial (Medina, 2018) . A 2013 review (Bulic et al., 2013) lists several classes of potential inhibitors/modulators of tau aggregation such as polyphenols, rhodanines, phenyl-thiazolylhydrazide, N-phenylamines, benzothiazoles, and aminothienopyridazines. Only few of these structures are expected to actually bind to and stabilize monomeric soluble tau; most inhibitors/modulators likely redirect the self-assembly toward 'off-pathway' oligomeric forms (Bulic et al., 2013) . In light of the topic of this review, such compounds are not considered modulators of normal dynamic behavior of tau. Moreover, many putative aggregation inhibitors have demonstrated to be potent in in vitro assays, but evidence of inhibiting tau aggregation in vivo and, even more importantly, cognitive improvement is still lacking (Medina, 2018) . It is also worth mentioning that the specificity of tau aggregation inhibitors, including methylene blue, is limited, and pleiotropic effects can be expected (Medina, 2018) . Harnessing the hyper-phosphorylation of aggregated tau (Grundke-Iqbal et al., 1986b) for therapy has been considered a viable approach for a long time. However, tau phosphorylation cannot solely be considered a pathological event because the protein's transient binding to MTs is likely to be regulated at least in part via phosphorylation as well (see 3.3) (Lindwall and Cole, 1984) . The kinases and phosphatases that have been demonstrated to be involved in tau phosphorylation comprise GSK3β, Cdk5, and p25 (Tell and Hilgeroth, 2013; Shukla et al., 2012) . Interfering with tau phosphorylation promises to affect protein homeostasis upstream of proteinaceous aggregation and remains a valuable strategy. However, the exact regulation as well as physiological and/or pathological significance of tau phosphorylation at all its different phosphorylation sites remain questions to be answered.
Lastly, while modifying the composition of the vesicles that αS binds to (e.g., via SCD inhibition) has emerged only recently as a new potential strategy for treating synucleinopathies (Fanning et al., 2018; Vincent et al., 2018) , tubulin-stabilizing compounds have already been tested in clinical trials (Morimoto et al., 2013; Boxer et al., 2014) , albeit unsuccessfully in phase III (Boxer et al., 2014) . MT imbalance is typically considered a downstream effect of tau dyshomeostasis. The interplay between αS and fatty acids/lipids/vesicles, however, may be more complicated. For example, a previous study demonstrated that expressing αS alters fatty acid composition of dopaminergic neurons in a way that reflects alterations in human brains with synucleinopathies (Sharon et al., 2003) . Genetic evidence, on the other hand, suggests that impaired glucocerebrosidase activity may be upstream of αS dyshomeostasis in PD pathogenesis (Aharon-Peretz et al., 2004; Goker-Alpan et al., 2006) . Mazzulli et al. proposed a 'bidirectional pathogenic loop' between glucocerebrosidase and αS (Mazzulli et al., 2011) . Other lipidrelated genes that emerged from GWAS as PD risk factors comprise a diacylglycerol kinase (DGKQ), which controls cellular diglyceride content (Simon-Sanchez et al., 2009; Simon-Sanchez et al., 2011; Chen et al., 2013; Nalls et al., 2014; Zhu et al., 2017) , and fatty acid elongase 7, a determinant of acyl-chain length and hence lipid composition/ membrane fluidity (Chang et al., 2017) . Both indicate that changes in lipid metabolism can be upstream of αS dyshomeostasis (which does not exclude additional effects on lipids downstream of αS). In turn, modifying cellular lipid composition could indeed help keep cellular αS folding homeostasis intact or correct it back to normal. A similar approach for correcting tau homeostasis via modification of MT biology may be less evident from genetics or the literature in general.
It is also important to note that in both tauopathies and synucleinopathies the pathway toward fibrillary assembly may be quite different from one disease to another. As far as the endpoints are concerned, there is growing evidence for disease-specific aggregate formation. For example, the single protofilaments with an elongated and loosely arranged structure found in Pick's Disease are markedly F. Yeboah, et al. Neurobiology of Disease 132 (2019) 104543 different from the compact bundles of C-shaped paired helical tau filaments found in AD Fitzpatrick et al., 2017) . Similarly, PD, DLB, and MSA have been reported to be characterized by distinct αS aggregate 'strains' that exhibit different 'seeding' characteristics (Peelaerts et al., 2015 (Peelaerts et al., , 2018 Yamasaki et al., 2019) , and the notion of non-fibrillar, membranous αS aggregation (Shahmoradian et al., 2019) adds further complexity. These differences in advanced pathology may point at differences in disease initiation. As a consequence, drugs targeting certain transient forms within tau and αS dynamic equilibria could be disease-specific and inefficient toward another assembly pathway.
